8-K: Arcellx Announces Positive Anito-Cel Data and Year-End 2024 Financial Results, Cash Runway Extends Into 2027

Arcellx reports positive clinical data for anito-cel in relapsed or refractory multiple myeloma and highlights a strong cash position extending into 2027.

Summary

• Arcellx announced its fourth quarter and year-end 2024 financial results and business highlights.
• The company presented positive preliminary data from the Phase 2 pivotal iMMagine-1 study of anito-cel, showing a 97% overall response rate (ORR) and a 62% complete response/stringent complete response (CR/sCR) rate at a median follow-up of 9.5 months.
• Notably, no delayed neurotoxicities were observed in 155 patients dosed across Phase 1 and iMMagine-1 studies.
• Anito-cel's commercial launch for relapsed or refractory multiple myeloma (RRMM) is planned for 2026.
• Arcellx ended the quarter with $626 million in cash, reiterating a cash runway into 2027.
• Collaboration revenue decreased slightly to $107.9 million for 2024, primarily due to the timing of the Kite Pharma collaboration agreement.
• Research and development expenses increased to $157.1 million for 2024, driven by increased personnel costs and program expenses.
• General and administrative expenses increased to $88.4 million for 2024, due to increased personnel costs, commercial readiness expenses, and depreciation.
• Net losses were $107.3 million for 2024.
• The company is planning an iMMagine-1 data update mid-year 2025 and expanding its ARC-SparX program in acute myeloid leukemia.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, a strong cash position, and a clear path towards commercialization, indicating a favorable outlook for the company.

Positives

• The iMMagine-1 study of anito-cel showed a high overall response rate of 97% and a complete response/stringent complete response rate of 62%.
• Anito-cel demonstrated a manageable safety profile with no delayed neurotoxicities observed.
• Arcellx has a strong cash position of $626 million, expected to fund operations into 2027.
• The company is progressing towards the commercial launch of anito-cel in 2026.
• High MRD negativity rate of 93.1% was achieved in patients evaluable for MRD testing.
• The 6-month PFS and OS rates were 93.3% and 96.5%, respectively, and 12-month PFS and OS rates were 78.5% and 96.5%, respectively.

Negatives

• Collaboration revenue decreased slightly from $110.3 million in 2023 to $107.9 million in 2024.
• Net losses increased from $70.7 million in 2023 to $107.3 million in 2024.
• Research and development expenses increased from $133.8 million in 2023 to $157.1 million in 2024.
• General and administrative expenses increased from $66.4 million in 2023 to $88.4 million in 2024.

Risks

• The commercial launch of anito-cel in 2026 is subject to FDA approval, which is not guaranteed.
• Clinical trial results are preliminary and may change as the studies progress.
• Increased operating expenses, including R&D and G&A, could impact the company's cash runway.
• The company's future performance depends on the success of its product candidates and collaborations.

Future Outlook

Arcellx plans to present updated data from the iMMagine-1 study mid-year 2025, prepare for the commercial launch of anito-cel in multiple myeloma in 2026, enroll its program in generalized myasthenia gravis, and expand its ARC-SparX program in acute myeloid leukemia.

Management Comments

• Rami Elghandour, Arcellx's Chairman and Chief Executive Officer, stated that 2024 was a transformational year for Arcellx.
• He highlighted the differentiated clinical profile of anito-cel for the potential treatment of patients with relapsed or refractory multiple myeloma.
• He noted the manageable safety profile of anito-cel with no delayed neurotoxicities.

Industry Context

The announcement highlights Arcellx's progress in the competitive field of cell therapies for multiple myeloma, where companies like Johnson & Johnson (with Carvykti) and Bristol Myers Squibb (with Abecma) are also developing BCMA-directed CAR T-cell therapies. Arcellx's anito-cel aims to differentiate itself through its D-Domain binder and manageable safety profile.

Comparison to Industry Standards

• The 97% ORR and 62% CR/sCR observed in the iMMagine-1 study compare favorably to other approved BCMA-directed CAR T-cell therapies like Carvykti (ciltacabtagene) and Abecma (idecabtagene vicleucel).
• For example, Carvykti demonstrated a 98% ORR and 78% sCR in the CARTITUDE-1 study, while Abecma showed a 73% ORR and 39% CR in the KarMMa trial.
• The absence of delayed neurotoxicities in Arcellx's anito-cel is a notable advantage, as neurotoxicity is a known risk with CAR T-cell therapies.
• Kite's manufacturing turnaround times being consistent with commercial products is a positive sign for scalability and commercial readiness, which is crucial for competing with established players like Gilead and Bristol Myers Squibb.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical data and extended cash runway.
• Patients with relapsed or refractory multiple myeloma may benefit from the potential availability of anito-cel.
• Employees can be encouraged by the company's progress and financial stability.
• The collaboration with Kite benefits both companies through shared development and commercialization efforts.

Next Steps

• Arcellx plans to present updated data from the iMMagine-1 study mid-year 2025.
• The company is preparing for the commercial launch of anito-cel in multiple myeloma in 2026.
• Arcellx will enroll its program in generalized myasthenia gravis.
• The company will expand its ARC-SparX program in acute myeloid leukemia.

Key Dates